help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gustavson, L. E.
Right arrow Articles by Benet, L. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gustavson, L. E.
Right arrow Articles by Benet, L. Z.

Journal of Clinical Endocrinology & Metabolism, Vol 62, 234-237, Copyright © 1986 by Endocrine Society

ARTICLES

Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens

LE Gustavson, UF Legler and LZ Benet

Companion studies were designed to determine the effects of oral contraceptives and conjugated estrogens on the pharmacokinetics of prednisolone. Twenty-four normal women entered the studies, including six young women taking oral contraceptives and six age-matched control women, and six postmenopausal women receiving conjugated estrogens and six age-matched postmenopausal women. All received 0.53 mg/kg prednisolone phosphate, iv. Significant decreases (P less than 0.05) in the clearance and volume of distribution and significant increases in the half-life were found for both total and unbound prednisolone in the women taking oral contraceptives compared to values in the young control women. A significant decrease in the unbound clearance and increases in the total and unbound half-lives of prednisolone were found in the women receiving conjugated estrogens compared to values in the postmenopausal control women. Total clearance and volume of distribution were unchanged by conjugated estrogen therapy. Administration of prednisolone to women receiving estrogen-containing oral contraceptives or conjugated estrogens results in exposure of these women to increased concentrations of unbound prednisolone for increased periods of time. Increases in the pharmacological and toxic effects of prednisolone might be expected in these women.


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Ines, E J P de Koning, F Buttgereit, M Cutolo, H Capell, et al.
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
Ann Rheum Dis, March 1, 2006; 65(3): 285 - 293.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
T. Shelepova, A. N. Nafziger, J. Victory, A. D. M. Kashuba, E. Rowland, Y. Zhang, E. Sellers, G. Kearns, J. S. Leeder, A. Gaedigk, et al.
Effect of a Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail
J. Clin. Pharmacol., December 1, 2005; 45(12): 1413 - 1421.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. B. Merkatz, R. Temple, S. Sobel, K. Feiden, D. A. Kessler, and The Working Group on Women in Clinical Trials
Women in Clinical Trials of New Drugs -- A Change in Food and Drug Administration Policy
N. Engl. J. Med., July 22, 1993; 329(4): 292 - 296.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society